急性心肌梗死是全球发病率和死亡率较高的疾病.尽管及时的再灌注策略可挽救濒死的心肌细胞,但继发于缺血-再灌注的炎症反应会造成额外的心肌损伤.人类对于动脉粥样硬化炎症机制的认知经历了漫长的岁月.1858年,Virchow提出"动脉粥样硬化是一种胆固醇诱发的慢性炎症",但未受到研究者的重视.2005年,1项发表在Circulation的研究表明,冠状动脉闭塞部位可以产生炎症因子白细胞介素6和血清淀粉样蛋白A.2019年,New England Journal of Medicine发表了 1篇关于低剂量秋水仙碱减少近期心肌梗死患者心血管事件的临床试验研究.至此,急性心肌梗死后的抗炎治疗越来越受到研究者的重视.本文对急性心肌梗死后抗炎治疗及其所涉及的机制的研究进行综述,为进一步的临床研究提供参考.
Progression of Anti-inflammatory Therapies in Acute Myocardial Infarction
Acute myocardial infarction(AMI)is a disease with high mortality and morbidity.Timely reperfusion therapy can salvage viable myocardium,but inflammatory response secondary to reperfusion injury will lead to extra myocardium damage.It took a long period of time for man to understand inflammatory mechanism of atherosclerosis.In 1858,Virchow put forward a theory called"atherosclerosis is a chronic inflammation induced by cholesterol",but it did not have much impact for several decades until 2005.In this year,Circulation issued an article that showed interleukin-6 and serumamyloid A can be detected in the site of coronary occlusion.In 2019,New England Journal of Medicine published a clinical study concerning low doses of colchicine can decrease major cardiovascular events.Therefore,researchers attach more and more importance to anti-inflammatory approach after AMI.This article reviewed the approaches and mechanisms of anti-inflammatory after AMI,in order to provide a reference for further clinical study.
NETL
NSTL
万方数据
